July 9th, 2025
AOI Biosciences Inc.
AOI Biosciences Inc. (Headquarters: Ibaraki, Osaka; CEO: Shinichi Sueta; hereinafter referred to as “AOI Bio.”), with its international commercialization partner Sumitomo Corporation (Head office: Chiyoda-ku, Tokyo, Japan; Representative Director, President and CEO: Shingo Ueno; hereinafter “Sumitomo Corporation”), has started providing services for the “β2GPI Neoself Antibody Test,” its novel test for recurrent pregnancy loss and recurrent implantation failure, in Malaysia. The β2GPI Neoself Antibody Test is now available at multiple medical institutions throughout Malaysia.
Additionally, AOI Bio. and Sumitomo Corporation will showcase the β2GPI Neoself Antibody Test at the “32nd International Congress of the Obstetrical and Gynaecological Society of Malaysia” to be held in Penang, Malaysia, from July 10 to 13, 2025. With the β2GPI Neoself Antibody Test, AOI Bio aims to contribute to the advancement of reproductive medicine in Malaysia.
Malaysian Clinics Offering the the β2GPI Neoself Antibody Test (In no particular order)*
Alpha IVF & Women’s Specialists (Petaling Jaya)
Alhaya Fertility Centre (Kuala Lumpur)
Thomson Fertility Centre (Petaling Jaya)
Victory IVF Fertility Centre (Johor Bahru)
Ever Link Fertility Centre (Shah Alam)
Sunfert Fertility Centre (Kuala Lumpur)
*Including hospitals preparing to offer testing.
About the β2GPI Neoself Antibody Test
This innovative blood test identifies neoself antibodies, which are implicated for miscarriages and thrombosis, accounting for approximately 20% of recurrent pregnancy loss cases. Recent studies have also reported a connection between these antibodies and infertility. Clinical research has demonstrated that, for patients with positive test results, implementing appropriate medical intervention led to a live birth rate approximately 1.7 times higher in recurrent pregnancy loss cases and a pregnancy rate more than twice as high in infertility cases. AOI Bio. holds exclusive rights, granted by Osaka University, to conduct this test. The test is also recognized as Advanced Medical Care1 within Japan.
(1)Advanced medical care refers to treatments and technologies not yet covered by Japan’s national health insurance, but still recognized by the Ministry of Health, Labour and Welfare (MHLW). These treatments can be provided to patients simultaneously with insurance-covered medical services, under specific standards for participating medical facilities and methods established by the government.
■ About AOI Biosciences Inc.
Company Name:AOI Biosciences Inc.(https://www.aoibio.com/en)
Business Overview:AOI Biosciences integrates bioinformatics with proprietary biotechnology, focusing on infectious diseases and autoimmune disorders. The company engages in diagnostic testing, drug discovery, and drug discovery support businesses, continuously contributing to the health and well-being of people worldwide.
Date of Incorporation:November 2019
■ For inquiries about this press release, contact
e-mail:hello@aoibio.com